Your browser doesn't support javascript.
loading
Anti-SARS-CoV-2 IgG antibody titer after BNT162b2 mRNA COVID-19 vaccination in Japanese patients who underwent renal replacement therapy, hemodialysis, peritoneal dialysis, and kidney transplantation.
Iwabuchi, Ryohei; Harada, Makoto; Yamada, Aiko; Aomura, Daiki; Yamada, Yosuke; Sonoda, Kosuke; Nakazawa, Hideyuki; Sakai, Kaoko; Mizukami, Etsuko; Hashimoto, Koji; Kamijo, Yuji.
Afiliação
  • Iwabuchi R; Department of Nephrology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan.
  • Harada M; Kashiwabara Clinic, 4565-1 Hotaka Kashiwabara, Azumino, 399-8304, Japan.
  • Yamada A; Department of Nephrology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan.
  • Aomura D; Kashiwabara Clinic, 4565-1 Hotaka Kashiwabara, Azumino, 399-8304, Japan.
  • Yamada Y; Department of Nephrology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan.
  • Sonoda K; Kashiwabara Clinic, 4565-1 Hotaka Kashiwabara, Azumino, 399-8304, Japan.
  • Nakazawa H; Department of Nephrology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan.
  • Sakai K; Department of Nephrology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan.
  • Mizukami E; Department of Nephrology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan.
  • Hashimoto K; Department of Hematology and Oncology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan.
  • Kamijo Y; Department of Hematology and Oncology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan.
Clin Exp Nephrol ; 27(8): 660-671, 2023 Aug.
Article em En | MEDLINE | ID: mdl-37095343
ABSTRACT

BACKGROUND:

Coronavirus disease (COVID-19) vaccination is recommended for patients undergoing renal replacement therapy (RRT), including hemodialysis (HD), peritoneal dialysis (PD), and kidney transplantation (KT). However, the difference in the immune response between RRT patients and healthy individuals after mRNA vaccines remains uncertain.

METHODS:

This retrospective observational study evaluated the anti-severe-acute-respiratory-syndrome-coronavirus-2 (anti-SARS-CoV-2) IgG antibody acquisition, titers and their changes, normal response rate (reaching titers of healthy individuals), factors associated with a normal response, and effectiveness of booster vaccination in Japanese RRT patients.

RESULTS:

Most HD and PD patients acquired anti-SARS-CoV-2 IgG antibodies after the second vaccination; however, their antibody titers and normal response rates (62-75%) were low compared with those of healthy subjects. Approximately 62% of KT recipients acquired antibodies, but the normal response rate was low (23%). Anti-SARS-CoV-2 IgG antibody waning occurred in the control, HD, and PD groups, while negative or very low titers remained in KT recipients. Third booster vaccination was effective in most HD and PD patients. However, the effect was mild in KT recipients - only 58% reached a normal response level. Multivariate logistic regression analyses demonstrated that younger age, higher serum albumin level, and RRT other than KT were significantly associated with a normal response after the second vaccination.

CONCLUSIONS:

RRT patients, particularly KT recipients, exhibited poor vaccine responses. Booster vaccination would be beneficial for HD and PD patients; however, its effect in KT recipients was mild. Further COVID-19 vaccinations using the latest vaccine or alternative procedures should be considered in RRT patients.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Rim / Diálise Peritoneal / COVID-19 Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Rim / Diálise Peritoneal / COVID-19 Idioma: En Ano de publicação: 2023 Tipo de documento: Article